Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. is registering $200,000,000 of common stock in a primary offering. The company has also granted underwriters a 30-day option to buy up to an additional $30,000,000 of common stock. Concurrently, a Covidien subsidiary of Medtronic may purchase up to $90.0 million of common stock in a private placement at the same price as this offering, for a stake between 16.0% and 19.99% of shares outstanding after the deals close.
Anteris develops the DurAVR THV System for treating severe aortic stenosis and is running the global PARADIGM pivotal trial following FDA IDE and initial European approvals. The company remains a development-stage business with recurring losses and preliminary cash and cash equivalents of about $12.6 million as of December 31, 2025, and its auditors have raised substantial doubt about its ability to continue as a going concern. Proceeds from this offering and the private placement are intended to fund PARADIGM trial execution, manufacturing expansion, R&D for v2vmedtech and general corporate purposes, and Anteris is also exploring up to $100 million of additional debt financing.
Anteris Technologies Global Corp. reported an equity transaction by its Chief Operating Officer and director. On December 16, 2025, the reporting person acquired 166,666 shares of common stock through the vesting and settlement of restricted stock units, recorded as a code "M" transaction. On the same date, 65,584 shares were disposed of in a code "F" transaction at a price of $4.95 per share, typically reflecting shares withheld to cover taxes. After these transactions, the reporting person directly held 101,082 shares of common stock.
The derivative table shows this activity came from a grant of 500,000 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16 of 2025, 2026, and 2027, subject to continued service. Following the reported transaction, 333,334 restricted stock units remained beneficially owned.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported the vesting of a portion of his equity award and the related share issuance. On December 16, 2024, he was granted 83,333 restricted stock units (RSUs), scheduled to vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to his continued service. On December 16, 2025, 27,777 RSUs vested and converted on a one-for-one basis into common stock, recorded as an acquisition of 27,777 shares at a price of $0.
Following this transaction, McDonnell beneficially owns 27,777 common shares indirectly through Citicorp Nominees Pty Ltd and 55,556 RSUs directly, each RSU convertible into one share of common stock. The common stock received is represented as CHESS Depositary Interests traded on the Australian Securities Exchange.
Anteris Technologies Global Corp. chief executive officer and director Wayne Paterson reported equity award activity involving the company’s common stock. On December 16, 2025, a tranche of 333,333 restricted stock units (RSUs) converted on a one-for-one basis into the same number of common shares, reflecting previously granted equity compensation.
The filing also shows a disposition of 163,213 common shares at $4.95 per share, typically consistent with share sales to cover tax withholding on vested awards. After these transactions, Paterson held 182,727 common shares indirectly through Citibank, N.A. London as custodian and 20,334 shares directly, along with 666,667 RSUs that remain outstanding. These RSUs are part of a 1,000,000-unit grant awarded on December 16, 2024, vesting in roughly equal installments on December 16 of 2025, 2026, and 2027, which stockholders approved on December 3, 2025.
Anteris Technologies Global Corp. director John Seaberg reported the vesting and conversion of restricted stock units into common stock. On 12/16/2025, 27,777 restricted stock units were converted into 27,777 shares of common stock in a transaction coded "M," increasing his directly held common shares to 43,635. He also holds 3,852 shares indirectly through Citibank, N.A. London as custodian.
The derivative table shows these 27,777 restricted stock units converting at an exercise price of $0 into common stock, leaving 55,556 restricted stock units beneficially owned following the transaction. These units come from a contingent grant of 83,333 restricted stock units awarded on December 16, 2024, which vest in approximately equal installments on December 16, 2025, 2026 and 2027, subject to continued service and approval previously obtained from stockholders on December 3, 2025.
Anteris Technologies Global Corp. filed a prospectus supplement linked to its Form S-1 registration statement covering up to 9,103,796 shares of common stock that may be sold from time to time by selling stockholders. The supplement incorporates information from a newly filed Current Report on Form 8-K.
The attached 8-K notes that on December 13, 2025 (December 14, 2025 in Australia), Stephen Denaro resigned, with immediate effect, from the Company’s Board of Directors as a Class II director, and his resignation was not due to any disagreement over operations, policies or practices. He will continue as corporate secretary of Anteris Technologies Pty Ltd and as a director of that and other Australian subsidiaries. The Company’s common stock trades on Nasdaq under the symbol AVR, which closed at $4.98 per share on December 12, 2025.
Anteris Technologies Global Corp. disclosed that Stephen Denaro resigned from its Board of Directors and as a Class II director, effective December 13, 2025. The company states that his resignation is not due to any disagreement with management or with its operations, policies, or practices, suggesting no underlying dispute at the board level.
Denaro will remain closely involved with the organization as corporate secretary of Anteris Technologies Pty Ltd and as a member of the boards of that company and other Australian subsidiaries. This shifts the composition of the U.S. parent’s board while maintaining leadership continuity within Anteris’s Australian entities.
Anteris Technologies Global Corp. director Gregory S. Moss reported receiving two grants of restricted stock units tied to the company’s common stock. One grant covers 52,742 restricted stock units, each representing a right to receive one share of common stock.
These 52,742 units vest in three approximately equal annual installments on June 7, 2026, 2027 and 2028, subject to his continued service. A second grant of 13,821 restricted stock units also represents one share of common stock per unit and vests on the earlier of the first anniversary of the grant date and the next annual stockholders meeting, subject to continued service.
Anteris Technologies Global Corp. is registering 9,103,796 shares of common stock for resale by existing investors. The shares consist of 2,346,936 already-issued shares, 2,346,936 shares issuable upon exercise of common stock warrants, 2,079,962 shares underlying CHESS Depositary Interests (CDIs), and 2,329,962 shares issuable upon exercise of CDI warrants. These securities were issued in an October–November 2025 private placement. Anteris will not receive proceeds from stockholder resales but could receive up to approximately $40.4 million if all related warrants are exercised at $7.50 per share for common stock warrants and A$11.50 per CDI for CDI warrants. As of September 30, 2025, 36,062,370 shares of common stock were outstanding. Anteris is a development-stage structural heart company focused on its DurAVR® transcatheter heart valve and the global PARADIGM pivotal trial in severe aortic stenosis; prior audited financials include an explanatory paragraph about substantial doubt regarding its ability to continue as a going concern.